Health Tech Capitol | WARF, Gregor join in prostate cancer study
16044
post-template-default,single,single-post,postid-16044,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

WARF, Gregor join in prostate cancer study

12 Sep WARF, Gregor join in prostate cancer study

Posted at 15:42h in Uncategorized by
0 Likes

Madison-based Gregor Diagnostics, a molecular diagnostics company, has entered into an exclusive license agreement with the Wisconsin Alumni Research Foundation around Gregor’s groundbreaking new screening test for prostate cancer.

According to a release, the agreement grants Gregor exclusive rights to intellectual property covering biomarkers that it anticipates developing and commercializing as part of a new screening test for the detection of prostate cancer from seminal fluid.

Read more at InBusiness Madison

No Comments

Sorry, the comment form is closed at this time.